Systemic Lupus Erythematosus | Disease Landscape and Forecast | G7 | 2018
SLE is an autoimmune condition characterized by varied symptoms and multiple organ involvement, making it a complex disease that is difficult to manage. Moreover, challenges in clinical trial design and in understanding the potential market for SLE therapies often impede drug development, leading to high failure rates of pipeline agents. Benlysta is the only approved biologic for SLE, which caters to a specific SLE population, leaving high unmet need in the SLE space. Pharmaceutical companies have identified the hidden commercial opportunity in this area, as such,the SLE pipeline has several agents in late-phase and many more in early-phase development. The SLE Disease Landscape & Forecast offers detailed insights into current medical practices, key unmet needs, and new developments in the SLE space, along with an analysis of opportunities and obstacles faced by emerging agents.
Questions Answered:
- How large is the drug-treated SLE population and how will it change over the 2017-2027 forecast period?
- How large is the treatable SLE population and how will diagnosis/drug-treatment rates change over time?
- What is the state of treatment in SLE? Which are the most important drugs and why?
- What are interviewed experts’ insights on current treatment options?
- What are the key unmet needs in SLE?
- Which novel therapies are most promising and what sales/uptake could they secure in SLE?
- What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the SLE market and how will the market evolve over the forecast period?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research:
Approximately 30 country-specific interviews with rheumatologists and nephrologists.
Epidemiology:
Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and lupus nephritis).Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.Emerging therapies: Phase II: 16 drugs; Phase III: 5 drugs; Coverage of 6 select preclinical and Phase I products.
